Lumen Bioscience
Our patented technology allows us to use the well-known food algae spirulina to deliver therapeutic proteins.
Seattle, United States
90 employees
Grant
Total: $66.95M
Biopharma, Biotechnology +1
General Information
Get notified when Lumen Bioscience moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Lumen Bioscience
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
United States Market
Biopharma
About Lumen Bioscience
Taxonomy: Therapeutic Proteins, Clinical-Stage, Oral Antibody Therapeutics, Topically Delivered Drugs, Mucosally Delivered Drugs, Industrial Biotechnology, Cyanobacteria, Pigments, Animal Health
Funding Rounds & Investors (9)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Grant | •••••• | 1 | •••• •••• | 17 Oct 2023 |
| Grant | •••••• | 1 | •••• •••• | 11 May 2023 |
| Grant | •••••• | 1 | •••• •••• | 23 Dec 2022 |
| Grant | •••••• | 1 |
|
27 Jan 2021 |
| Grant | •••••• | 1 |
|
24 Sep 2020 |
Lumen Bioscience Alternatives & Competitors
Small molecule therapies for obesity and metabolic disorders, delivered orally
Our mission is to bring life-changing therapies to individuals living with Angelman syndrome (AS).
vs
Biopharm
FAQ About Lumen Bioscience
Don't just browse. Track.
Signal Tracker monitors Lumen Bioscience and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.